Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults

• Published in: American journal of preventive medicine 2022-04, Vol.62 (4), p.519-528
• Main Authors: Chen, Cheng, Lo-Ciganic, Wei-Hsuan, Winterstein, Almut G., Tighe, Patrick, Wei, Yu-Jung J.
• Format: Article
• Language: English
• Subjects: Aged; Analgesics, Opioid - adverse effects; Beneficiaries; Chronic pain; Chronic Pain - drug therapy; Chronic Pain - epidemiology; Critical incidents; Cross-Sectional Studies; Drug interactions; Health risks; Humans; Inappropriateness; Medical diagnosis; Medicare; Narcotics; Nervous system; Older people; Opioids; Pain; Patient safety; Polypharmacy; Prescription drugs; Prescriptions; Risk factors; Trends; United States - epidemiology
• ISSN: 0749-3797; 1873-2607
• DOI: 10.1016/j.amepre.2021.08.024

Concurrent use of prescription opioids with gabapentinoids may pose risks of serious drug interactions. Yet, little is known about the trends in and patient characteristics associated with concurrent opioid–gabapentinoid use among older Medicare opioid users with chronic noncancer pain. A cross-sectional study was conducted among Medicare older beneficiaries (aged ≥65 years) with chronic noncancer pain who filled ≥1 opioid prescription within 3 months after a randomly selected chronic noncancer pain diagnosis (index date) in a calendar year between 2011 and 2018. Patient characteristics were measured in the 6-month baseline before the index date, and concurrent opioid–gabapentinoid use for ≥1 day was measured in the 3-month follow-up after the index date. Multivariable modified Poisson regression hwas used to assess the trends and characteristics of concurrent opioid–gabapentinoid use. Analyses were conducted from January to June 2021. Among 464,721 eligible older beneficiaries with chronic noncancer pain and prescription opioids, the prevalence of concurrent opioid–gabapentinoid use increased from 17.0% in 2011 to 23.5% in 2018 (adjusted prevalence ratio=1.48, 95% CI=1.45, 1.53). Concurrent users versus opioid-only users tended to be non-Black, low-income subsidy recipients, and Southern residents. The clinical factors associated with concurrent opioid–gabapentinoid use included having a diagnosis of neuropathic pain, polypharmacy, and risk factors for opioid-related adverse events. Concurrent opioid–gabapentinoid use among older Medicare beneficiaries with chronic noncancer pain and prescription opioids has increased significantly between 2011 and 2018. Future studies are warranted to investigate the impact of concurrent use on outcomes in older patients. Interventions that reduce inappropriate concurrent use may target older patients with identified characteristics.